Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study

NCT02041247 is registered in ClinicalTrials.gov with InnaVirVax as lead sponsor.

NCT NCT02041247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02041247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study
Lead sponsor
InnaVirVax
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2014
Completion date
November 30, 2016
Enrollment
90 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hiv